Evidence map›Paper›PMID 17060526›Full record

ArticleAntimicrobial agents and chemotherapy2007

Quinupristin-dalfopristin nonsusceptibility in pneumococci from sickle cell disease patients.

Caroline A Obert, Martha L Miller, Jeremy Montgomery, Thomas Adamkiewicz, Elaine I Tuomanen

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 90% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Caroline A ObertDepartment of Infectious Diseases, St. Jude Children's Research Hospital, 332 North Lauderdale St., Memphis, TN 38105-2794, USA.
Martha L Miller
Jeremy Montgomery
Thomas Adamkiewicz
Elaine I Tuomanen
St. Jude Children's Research Hospital · USMorehouse School of Medicine · US

Funding

Y-Globin Gene Therapy Using In Vivo SelectionU54HL070590 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI PERSONS, DEREK A · 2003 to 2011
$13.8M
CONTROL OF AUTOLYSIS IN PNEUMOCOCCIR01AI039482 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI TUOMANEN, ELAINE I · 1997 to 2006
$1.7M
NHLBI NIH HHS U54 HL070590NHLBI NIH HHS U54HL070590NIAID NIH HHS R01 AI039482NIAID NIH HHS R01AI39482
6 · The paper itself

Abstract

Sickle cell disease (SCD) is a risk factor for fatal pneumococcal infection. Nonsusceptibilty to quinupristin-dalfopristin (Q-D) was absent from 105 non-SCD-associated pneumococcal isolates but was present in 33/148 (22%) SCD-associated isolates. One-third of the isolates harbored a known resistance mechanism. Q-D is not optimal for use for the treatment of pneumococcal infection in SCD patients.

Indexed as

Anemia, Sickle CellAnti-Bacterial AgentsClindamycinDrug Resistance, BacterialErythromycinHumansMicrobial Sensitivity TestsPhylogenyPneumococcal InfectionsSerotypingStreptococcus pneumoniaeVirginiamycinAnti-Bacterial AgentsClindamycinErythromycinquinupristin-dalfopristinVirginiamycin

Identifiers

PMID17060526
PMCPMC1797651
OpenAlexW2016675277

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.